Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043869 | 0.89 | BACE1 (0.57) | BACE1BACE2CTSD | |
| SCHEMBL6043858 | 0.82 | BACE1 (0.62) | BACE1BACE2CTSD | |
| SCHEMBL8364786 | 0.80 | BACE1 (0.71) | BACE1BACE2CTSD | |
| SCHEMBL5348605 | 0.79 | BACE1 (0.88) | BACE1BACE2CTSD | |
| SCHEMBL5363946 | 0.79 | BACE1 (0.74) | BACE1BACE2CTSD | |
| SCHEMBL5354471 | 0.79 | BACE1 (0.87) | BACE1BACE2CTSD | |
| SCHEMBL6043864 | 0.79 | BACE1 (0.56) | BACE1BACE2CTSD | |
| SCHEMBL5367552 | 0.78 | BACE1 (0.69) | BACE1BACE2CTSD | |
| SCHEMBL3350491 | 0.78 | BACE1 (0.77) | BACE1BACE2CTSD | |
| SCHEMBL3350500 | 0.78 | BACE1 (0.77) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763646-B2 | Compounds for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763646-B2 | Compounds for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763646-B2 | Compounds for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20060128786-A1 | Compounds for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2004029019-A2 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128786-A1 | Compounds for the treatment of alzheimer's disease | BACE1, BACE2, APP | BACE1 1/4885BACE2 2/4885CTSD 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.